A Phase Ib Study of Selumetinib in Patients with Previously Treated or Untreated Advanced/Metastatic NSCLC Who are Receiving Standard Chemotherapy Regimens
Phase of Trial: Phase I
Latest Information Update: 05 Apr 2019
Price : $35 *
At a glance
- Drugs Selumetinib (Primary) ; Carboplatin; Cisplatin; Paclitaxel; Pemetrexed
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- 02 Apr 2019 Status changed from active, no longer recruiting to completed.
- 11 Feb 2019 Planned End Date changed from 1 Dec 2018 to 1 Dec 2019.
- 13 Oct 2018 Results published in the Investigational New Drugs